SK bioscience Co.,Ltd.
302440.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.6T
Close$
Share Statistics
| Market cap | $2.60 Trillion |
|---|---|
| Enterprise Value | $3.15 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-718.26 |
| Beta | 0.88 |
| Outstanding Shares | 78,457,000 |
Return
| Return on Equity | -4.54% |
|---|---|
| Return on Assets | -2.66% |
| Return on Invested Capital | -8.45% |
Valuation & Multiples
| P/E Ratio | -31.09 |
|---|---|
| PEG | 214.35 |
| Price to Sales | 3.95 |
| Price to Book Ratio | 1.3 |
| Enterprise Value to Revenue | 4.78 |
| Enterprise Value to EBIT | -14.07 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 23, 2026
EPS Estimate
$-387.97
Average shareholder expectationRevenue Estimate
$179.00 B
Average shareholder expectationNext Earnings Call
Expected Date
October 26, 2026
EPS Estimate
$-387.97
Average shareholder expectationRevenue Estimate
$179.00 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SK bioscience Co.,Ltd.
984 employees
CEO: Jae-Yong Ahn SK bioscience Co.,Ltd. is a pharmaceutical firm focused on the discovery, development, production, and worldwide commercialization of vaccines and other biopharmaceutical products. Its current range of marketed vaccines includes Skycellf...